Clinical Trial Update: An Exploratory Trial to Assess the Improvement of Adverse Events in Chronic Myelogenous Leukemia Patients Treated With Imatinib When Switched to Nilotinib Treatment [Phase 4]

View source ↗

Summary

Phase 4 exploratory trial evaluating adverse event improvement when chronic myeloid leukemia patients switch from imatinib to nilotinib.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Myeloid Leukemia

Drugs mentioned

• Imatinib (imatinib)
• Nilotinib (nilotinib)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Chronic Myelogenous Leukemia | Phase 4 | Status: COMPLETED | Results posted: 2021-07-01